Adams Wealth Management Acquires Shares of 5,893 Gilead Sciences, Inc. $GILD

Adams Wealth Management bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 5,893 shares of the biopharmaceutical company’s stock, valued at approximately $653,000.

Other hedge funds have also modified their holdings of the company. Caldwell Trust Co purchased a new stake in shares of Gilead Sciences in the second quarter valued at approximately $121,000. Valeo Financial Advisors LLC boosted its position in shares of Gilead Sciences by 26.9% during the 2nd quarter. Valeo Financial Advisors LLC now owns 13,278 shares of the biopharmaceutical company’s stock worth $1,472,000 after purchasing an additional 2,811 shares in the last quarter. NWF Advisory Services Inc. boosted its position in shares of Gilead Sciences by 16.0% during the 2nd quarter. NWF Advisory Services Inc. now owns 2,162 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 299 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of Gilead Sciences by 3.6% during the 2nd quarter. Osaic Holdings Inc. now owns 204,115 shares of the biopharmaceutical company’s stock worth $22,650,000 after purchasing an additional 7,166 shares during the period. Finally, Total Investment Management Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $61,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 2.3%

Shares of NASDAQ:GILD opened at $120.40 on Monday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The stock’s fifty day simple moving average is $121.89 and its 200-day simple moving average is $115.81. The company has a market capitalization of $149.38 billion, a P/E ratio of 18.67, a P/E/G ratio of 0.67 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total transaction of $313,075.00. Following the transaction, the chief financial officer owned 154,555 shares of the company’s stock, valued at $19,354,922.65. This represents a 1.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This represents a 67.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 130,257 shares of company stock valued at $15,991,492 in the last 90 days. Insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research analyst reports. Truist Financial assumed coverage on shares of Gilead Sciences in a report on Monday, November 24th. They set a “buy” rating and a $140.00 price objective on the stock. HSBC boosted their price target on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. BMO Capital Markets set a $135.00 target price on Gilead Sciences in a research report on Tuesday, November 25th. Finally, Argus raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.13.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.